Search results
Showing 1036 to 1050 of 2581 results for methods
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer (TA100)
Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer in adults.
Sutureless aortic valve replacement for aortic stenosis (HTG483)
Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults. This involves removing the narrowed aortic valve and replacing it with an artificial valve that holds itself in place.
View recommendations for HTG483Show all sections
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Evidence-based recommendations on mirikizumab (Omvoh) for previously treated moderately to severely active Crohn's disease in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)
Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.
View recommendations for HTG728Show all sections
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.